Welcome to our dedicated page for Iradimed SEC filings (Ticker: IRMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
iRadimed Corporation filings document the public-company reporting for a Nasdaq-listed medical-device manufacturer focused on MRI-compatible infusion and patient-monitoring systems. Form 8-K reports furnish quarterly and annual operating results, dividend announcements, guidance updates and other material events tied to the company’s common stock.
Proxy and governance filings describe annual meeting proposals, director elections, auditor ratification, executive compensation, board committee matters and shareholder voting results. Other 8-K disclosures record board composition changes and related committee assignments, providing formal records of governance and capital-structure matters for IRMD.
IRADIMED CORP insider activity: A trust associated with CEO, President and Chairman Roger E. Susi reported three planned sales of common stock on January 20, 2026 under a Rule 10b5-1 trading plan adopted on June 16, 2025. The Phillip Susi 2008 Dynasty Trust sold 2,129 shares at a weighted average price of $101.03, 1,074 shares at $102.03, and 1,797 shares at $102.70. After these transactions, that trust held 2,267,500 shares of IRADIMED common stock. The filing also shows indirect holdings of 162,950 shares by the Roger E. Susi Revocable Trust and 2,062,500 shares by the Matthew Susi 2008 Dynasty Trust, with the reporting person disclaiming beneficial ownership beyond his pecuniary interest.
IRADIMED Corp insider trusts reported planned stock sales. Trusts associated with CEO, President and Chairman Roger E. Susi sold a total of 5,000 shares of IRADIMED common stock on January 12, 2026 under a pre-arranged Rule 10b5-1 trading plan adopted on June 16, 2025.
The Phillip Susi 2008 Dynasty Trust sold 4,888 shares at a weighted average price of $97.43 and 112 shares at $98.15, leaving it with 2,272,500 shares indirectly reported. Additional indirect holdings reported include 162,950 shares held by the Roger E. Susi Revocable Trust and 2,062,500 shares held by the Matthew Susi 2008 Dynasty Trust, with beneficial ownership disclaimed except to the extent of pecuniary interest.
IRADIMED Corporation insider activity centered on trust-held shares linked to its CEO. A trust associated with CEO, President and Chairman Roger E. Susi, the Phillip Susi 2008 Dynasty Trust, sold a total of 5,000 shares of IRADIMED common stock on January 5, 2026 in multiple transactions coded as open-market sales.
The reported weighted average sale prices ranged from $95.10 to $99.48, with underlying trade price ranges disclosed between $94.55 and $99.60, all under a Rule 10b5-1 trading plan adopted on June 16, 2025. After these sales, the Phillip Susi 2008 Dynasty Trust held 2,277,500 shares, while additional indirect holdings reported for Roger E. Susi were 162,950 shares through the Roger E. Susi Revocable Trust and 2,062,500 shares through the Matthew Susi 2008 Dynasty Trust.
Iradimed Corp’s CEO, president, chairman and 10% owner Roger E. Susi reported insider sales of the company’s common stock. On 12/15/2025, a Rule 10b5-1 trading plan arranged for the sale of 4,269 shares at a weighted average price of $96.68 and 731 shares at a weighted average price of $97.13, both through the Phillip Susi 2008 Dynasty Trust.
After these transactions, the form reports indirect beneficial ownership of 2,292,500 shares by the Phillip Susi 2008 Dynasty Trust, 162,950 shares by the Roger E. Susi Revocable Trust, and 2,062,500 shares by the Matthew Susi 2008 Dynasty Trust. The filing notes the trades were executed under a pre-established Rule 10b5-1 trading plan adopted on June 16, 2025, and that beneficial ownership of certain securities is disclaimed except to the extent of pecuniary interest.
Iradimed Corporation director Hilda Scharen-Guivel reported receiving 1,026 restricted stock units on December 11, 2025 under the company’s 2023 Equity Incentive Plan. The units were granted at a price of $0 and each restricted stock unit converts into one share of common stock.
The restricted stock units vest in two equal annual installments beginning on December 11, 2026, spreading the award over two years. After this grant, she beneficially owns 1,932 derivative securities, held directly.
Iradimed Corporation reported that one of its directors received an equity award of 1,026 restricted stock units (RSUs) on December 11, 2025 under the company’s 2023 Equity Incentive Plan. Each RSU converts into one share of common stock when it vests, so this grant represents the right to receive the same number of common shares in the future.
The RSUs vest in two equal annual installments beginning on December 11, 2026, aligning the director’s compensation with longer-term company performance. After this grant, the director beneficially owns 1,932 RSUs, all held as a direct ownership interest.
Iradimed Corporation director Monty K. Allen reported an equity award of derivative securities. On December 11, 2025, he received 1,026 restricted stock units (RSUs) under Iradimed Corporation's 2023 Equity Incentive Plan.
The RSUs convert into common stock on a one-for-one basis. They vest in two equal annual installments beginning on December 11, 2026, and upon each vesting date he will receive one share of common stock for each vested RSU. Following this grant, he beneficially owns 1,932 RSUs directly.
Iradimed Corporation reported an insider equity transaction by an officer serving as Chief Commercial Officer. On December 11, 2025, the officer converted 996 restricted stock units into common stock and disposed of 309 shares at $97.38 per share, resulting in 687 shares of common stock held directly afterward.
The restricted stock units were granted under Iradimed’s 2023 Equity Incentive Plan and convert into common stock on a one-for-one basis. They vest in three equal annual installments beginning on December 11, 2025. Following this activity, the officer beneficially owned 1,994 restricted stock units in addition to the directly held common stock.
Iradimed Corporation director Hilda Scharen-Guivel reported acquiring 905 shares of common stock through the conversion of restricted stock units. The transaction on December 11, 2025 is coded "M", indicating an exercise or conversion of derivative securities, and increased her directly held common stock to 8,598 shares. A related entry in the derivative table shows 905 restricted stock units converting into 905 common shares at an exercise price of $0, leaving 906 restricted stock units beneficially owned. The restricted stock units were granted under Iradimed Corporation's 2023 Equity Incentive Plan and vest in two equal annual installments beginning on December 11, 2025, with shares of common stock delivered as each installment vests.
Iradimed Corporation reported an insider equity transaction by director James B. Hawkins. On December 11, 2025, 905 shares of common stock were acquired following the conversion of restricted stock units, at an exercise price of $0. After this transaction, Hawkins directly beneficially owns 29,647 shares of Iradimed common stock.
The derivative position involved 905 restricted stock units that converted into an equal number of common shares on a one-for-one basis. These units were originally granted on December 11, 2024 under Iradimed Corporation's 2023 Equity Incentive Plan and vest in two equal annual installments beginning on December 11, 2025. Following the reported transaction, 906 restricted stock units remain beneficially owned.